Semaglutide Reprograms Macrophages via the GLP-1R/PPARG/ACSL1 Pathway to Suppress Papillary Thyroid Carcinoma Growth
The Journal of Clinical Endocrinology & Metabolism · 16.09.2025 · 110 (10) · 2777-2789
DOI: 10.1210/clinem/dgaf053 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 05.02.2025. Verfasst von Longlong Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thyroid Surgery, the First Affiliated Hospital of Zhengzhou University, Engineering Research Center of Multidisciplinary Diagnosis and …. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Glucagon-Like Peptides, Thyroid Cancer, Papillary, Glucagon-Like Peptide-1 Receptor. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Medical Science and Technology Project of Henan Province.
Abstract (Originalsprache)
Context
The use of glucagon-like peptide-1 receptor (GLP-1R) agonists such as semaglutide, a novel class of antidiabetic medications, has raised concerns about potential adverse effects, particularly a possible association with thyroid cancer (TC).
Objective
This study aims to evaluate whether semaglutide influences the progression of TC by modulating tumor-associated macrophages (TAMs).
Methods
Semaglutide was administered to human papillary thyroid carcinoma (PTC) xenograft mouse models, coculture systems consisting of human THP-1 macrophage cells and PTC cells, and primary murine peritoneal macrophages. Assessments included tumor size, M1/M2 macrophage ratio, PTC cell proliferation, and polarization marker expression.
Results
Semaglutide did not significantly impact the proliferation of PTC cells but reduced tumor size and inhibited the proliferation of PTC cells in coculture systems. It increased M1 and decreased M2 macrophages, reprogramming polarization by downregulating PPARG expression. Cotreatment with semaglutide and a PPARG agonist in the coculture system confirmed the upregulation of downstream genes RSAD2, ACSL1, and PLA2G7. Silencing ACSL1 inhibited lipid accumulation in THP-1 cells and promoted polarization toward the M2 macrophage phenotype.
Conclusion
Semaglutide modulates macrophage lipid metabolism through the GLP-1R/PPARG/ACSL1 signaling pathway. This modulation promotes the conversion of TAMs to the M1 macrophage phenotype, enhancing their anticancer activity. These findings suggest that semaglutide may improve therapeutic strategies, reduce unnecessary thyroid nodule screenings, and broaden its clinical applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thyroid Surgery, the First Affiliated Hospital of Zhengzhou University, Engineering Research Center of Multidisciplinary Diagnosis and Treatment of Thyroid Cancer of Henan Province, Key Medicine Laboratory…
- Department of Liver Transplantation, the First Affiliated Hospital of Zhengzhou University of Henan Province, Zhengzhou 450052, China.
ORCID-Profile: Detao Yin
Förderung
- Key Medical Science and Technology Project of Henan Province
Zitieren
APA
Wang, L., Zhang, L., Ma, R., Zhang, Y., Chang, Q., & Yin, D. (2025). Semaglutide Reprograms Macrophages via the GLP-1R/PPARG/ACSL1 Pathway to Suppress Papillary Thyroid Carcinoma Growth. The Journal of Clinical Endocrinology & Metabolism, 110(10), 2777-2789. https://doi.org/10.1210/clinem/dgaf053
Vancouver
Wang L, Zhang L, Ma R, Zhang Y, Chang Q, Yin D. Semaglutide Reprograms Macrophages via the GLP-1R/PPARG/ACSL1 Pathway to Suppress Papillary Thyroid Carcinoma Growth. The Journal of Clinical Endocrinology & Metabolism. 2025;110(10):2777-2789. doi:10.1210/clinem/dgaf053
BibTeX
@article{Wang2025,
author = {Wang, Longlong and Zhang, Lele and Ma, Runsheng and Zhang, Yifei and Chang, Qungang and Yin, Detao},
title = {Semaglutide Reprograms Macrophages via the GLP-1R/PPARG/ACSL1 Pathway to Suppress Papillary Thyroid Carcinoma Growth},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
volume = {110},
number = {10},
pages = {2777--2789},
doi = {10.1210/clinem/dgaf053}
}
EUVIMED